Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

GSK Receives WHO Approval For Adjuvanted H1N1 Vaccine

Posted by Jane Akre
Tuesday, December 01, 2009 12:05 PM EST
Category: Protecting Your Family
Tags: Swine Flu, Centers for Disease Control and Prevention, H1N1, Influenza, Public Health, WHO

Glaxo just received approval from the WHO to distribute its adjuvanted swine flu vaccine to developing countries.

WHO Approves Glaxo’s Swine Flu With Adjuvant



GlaxoSmithKline PLC has just received approval from the World Health Organization (WHO) for one of its swine flu vaccines.

The vaccine, called Arepanrix, will be produced in Canada and contains an adjuvant, a chemical compound that makes the vaccine more powerful, theoretically allowing less of the active ingredients to be used.

The WHO will make available 156 million doses of swine flu vaccine to 95 poor countries beginning this month.

GSK in a statement said the WHO approved its Canadian vaccine after examining data on quality and safety.

Last month, the drug giant advised health authorities not to use one batch of its Canadian-manufactured swine flu vaccine because of the possibility it could trigger more allergic reactions than normal including a life-threatening side effect, anaphylactic shock, reports the Wall Street Journal.

172,000 doses of the batch had been distributed across Canada.

GSK is one of four companies providing swine flu shots, the fifth, AstraZeneca’s MedImmune unit, produces the nasal spray.

None of the vaccines for the U.S. contain an adjuvant, according to the Food and Drug Administration. They have not been approved for use in the U.S. but are used in Europe.


Adjuvants are mixed and added to vaccines to trigger a stronger response to the antigen that induces immunity. An adjuvant may boost the strength of the antigen by as much as 10-fold, but they are not without controversy.

One adjuvant, known as MF-59, has yet to be approved by the FDA and has been linked to the Gulf War Syndrome.

In July, Health and Human Services said it was buying the ingredients separately for $884 million in case there was not enough swine flu vaccine to go around in the U.S.

The funds were used to purchase bulk H1N1 antigen and adjuvant from Sanofi Pasteur, MedImmune, GlaxoSmithKline and Novartis. The U.S. retains its stockpile of adjuvants.

Glaxo spokeswoman, Lisa Behrens says its adjuvant has been proven safe in clinical trials with 39,000 people.

The World Health Organization recommended in July that adjuvants be used to boost the quantity of vaccine globally. #

1 Comment

Anonymous User
Posted by Sentha K
Wednesday, December 02, 2009 7:04 PM EST

I heard that this adjuvant has RNA gp120 from HIV. Is that true? If so please explain the antigen antibody complex that generates during the initial activation of immunity.

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes